Leslie Oleksowicz MD

Oncology•Cincinnati, OH

Hematologic Oncology

Associate Professor of Medicine and Director of Medical Genitourinary Oncology at The Barrett Cancer Center of University Hospital, University of Cincinnati.

Join to View Full Profile

234 Goodman StBarrett CenterCincinnati, OH 45219
Phone+1 513-584-6928
Fax+1 513-584-4281

Education & Training

Icahn School of Medicine at Mount SinaiFellowship, Hematology and Medical Oncology, 1988 - 1989
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 1982 - 1984
Tufts University School of MedicineClass of 1982

Certifications & Licensure

NY State Medical License 1984 - 2027
OH State Medical License 2003 - 2026
CT State Medical License 2013 - 2015
MO State Medical License 2012 - 2014
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer Start of enrollment: 2006 Sep 26
ACTIVE_NOT_RECRUITING
PHASE3
S0500 Treatment Decision Making Based on Blood Levels of Tumor Cells for Metastatic Breast Cancer Treated With Chemo Start of enrollment: 2006 Oct 01
Completed
Phase 3
The High-Dose Aldesleukin (IL-2) "Select" Trial for Patients With Metastatic Renal Cell Carcinoma
COMPLETED
PHASE2
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor Start of enrollment: 2007 Dec 01
ACTIVE_NOT_RECRUITING
PHASE3
A Study of Amifostine (Ethyol) in Patients With Colorectal Cancer Start of enrollment: 2006 Oct 01
Terminated
Phase 2
Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Start of enrollment: 2008 Dec 01
ACTIVE_NOT_RECRUITING
PHASE2
Phase II Study Of Neoadjuvant Chemotherapy In Borderline Resectable Pancreatic Adenocarcinoma Start of enrollment: 2008 Aug 01
Withdrawn
Phase 2
S0802 - Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer Start of enrollment: 2009 May 01
Completed
Phase 2
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases Start of enrollment: 2008 Dec 01
Completed
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
Completed
Phase 3
S0910 Epratuzumab, Cytarabine, and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia Start of enrollment: 2010 Sep 01
Completed
Phase 2
Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy Start of enrollment: 2010 Sep 15
Terminated
Phase 3
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer Start of enrollment: 2011 Jan 01
Completed
Phase 2
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
ACTIVE_NOT_RECRUITING
PHASE3
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery Start of enrollment: 2011 May 25
ACTIVE_NOT_RECRUITING
PHASE3
Join now to see all

Publications & Presentations

PubMed

113 citations
The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma.
David F. McDermott, Su Chun Cheng, Sabina Signoretti, Kim Margolin, Joseph I. Clark
Clinical Cancer Research. 2015-02-01
28 citations
Secretory phospholipase A2-IIa is a target gene of the HER/HER2-elicited pathway and a potential plasma biomarker for poor prognosis of prostate cancer†
Leslie Oleksowicz, Yin Liu, R. Bruce Bracken, Krishnanath Gaitonde, Barbara Burke
The Prostate. 2012-07-01
14 citations
Vav3 oncogene is involved in regulation of secretory phospholipase A2-IIa expression in prostate cancer.
Zhongyun Dong, Yin Liu, Linda Levin, Leslie Oleksowicz, Jiang Wang
Oncology Reports. 2011-06-01

Professional Memberships

American Society of Clinical Oncology - ASCO
Member